Search Result

Results for "

LPA

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Acyltransferase (1) Adenosine Receptor (1) Akt (2) Apolipoprotein (4) Apoptosis (5) Autophagy (6) Biochemical Assay Reagents (6) Calcium Channel (8) Caspase (1) Cyclophilin (1) Drug Derivative (2) Drug Isomer (2) Endogenous Metabolite (6) G Protein-coupled Receptor Kinase (GRK) (1) HIV (4) Interleukin Related (3) Isotope-Labeled Compounds (4) LDLR (2) Liposome (1) LPL Receptor (65) MDM-2/p53 (1) Mitosis (2) mTOR (1) p38 MAPK (2) Phosphodiesterase (PDE) (16) PI3K (1) PKA (6) PKC (6) PPAR (2) Ras (1) Reactive Oxygen Species (ROS) (1) Reference Standards (9) Ribosomal S6 Kinase (RSK) (1) ROCK (9) Small Interfering RNA (siRNA) (2) TGF-beta/Smad (1) TGF-β Receptor (1) TRP Channel (1) YAP (2)
By Research Areas:	Cancer (41) Cardiovascular Disease (18) Endocrinology (3) Infection (3) Inflammation/Immunology (32) Metabolic Disease (13) Neurological Disease (23)
Click Chemistry:	Alkynes (1)
Oligonucleotides:	Phospholipids (9) siRNA drugs (1) Human Pre-designed siRNA Sets (1) siRNAs (2)

124

Inhibitors & Agonists

Fluorescent Dye

Biochemical Assay Reagents

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Antibodies

Click Chemistry

Oligonucleotides

GMP Molecules

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-107614

1-Oleoyl lysophosphatidic acid sodium 3 Publications Verification 1-Oleoyl-sn-glycero-3-phosphate sodium; 1-Oleoyl-LPA sodium	LPL Receptor Mitosis	Neurological Disease
1-Oleoyl lysophosphatidic acid (1-Oleoyl-sn-glycero-3-phosphate) sodium, a potent bioactive phospholipid, is a LPA receptor activator. 1-Oleoyl lysophosphatidic acid sodium can promote mitosis by inducing DNA synthesis. 1-Oleoyl lysophosphatidic acid sodium is also involved in normal and pathological emotional responses, including anxiety and depression .

HY-139853

BMS-986278 1 Publications Verification AdmiLPArant	LPL Receptor	Others
BMS-986278 is a potent and orally active lysophosphatidic acid receptor 1 (LPA1) antagonist, with K_bs of 6.9 nM and 4.0 nM for human and mouse LPA1, respectively. BMS-986278 can be used for the research of pulmonary fibrotic diseases .

HY-137862

1-Oleoyl lysophosphatidic acid 3 Publications Verification 1-Oleoyl-sn-glycero-3-phosphate; 1-Oleoyl-LPA	LPL Receptor	Neurological Disease
1-Oleoyl lysophosphatidic acid (1-Oleoyl-sn-glycero-3-phosphate) is an abundant lysophosphatidic acid (LPA) species with high biological activity due to its strong affinity for the LPA receptors. 1-Oleoyl lysophosphatidic acid is commonly used in most laboratories as a reagent for LPA receptor activation . 1-Oleoyl lysophosphatidic acid increases SRE-driven β-galactosidase activity .

HY-13285

Ki16425 10+ Cited Publications Debio 0719	LPL Receptor YAP	Neurological Disease Cancer
Ki16425 (Debio 0719) is a subtype-selective, competitive antagonist of the EDG-family receptors, *LPA1* and *LPA3* with K_is of 0.34 μM and 0.93 μM, respectively. Ki16425 (Debio 0719) reduces the *LPA*-induced activation of p42/p44 MAPK . Ki16425 can also inhibit *LPA*-induced dephosphorylation of Yes-associated protein (YAP)/TAZ in HEK293A cells .

HY-15277

AM966 15+ Cited Publications	LPL Receptor	Inflammation/Immunology
AM966 is a high affinity, selective, oral *LPA₁*-antagonist, inhibits LPA-stimulated intracellular calcium release (IC₅₀=17 nM).

HY-16040

AM095 free acid 10+ Cited Publications	LPL Receptor	Inflammation/Immunology
AM095 (free acid) is a potent *LPA1* receptor antagonist with IC₅₀ values of 0.98 and 0.73 μM for recombinant human or mouse LPA1 respectively.

HY-16039

AM095 10+ Cited Publications	LPL Receptor	Inflammation/Immunology
AM095 is a selective *LPA₁* receptor antagonist. The IC₅₀ for AM095 antagonism of LPA-induced calcium flux of human or mouse LPA₁-transfected CHO cells is 0.025 and 0.023 μM, respectively.

HY-132222

SET2 1 Publications Verification	TRP Channel	Cancer
SET2 is a selective TRPV2 antagonist (IC₅₀=0.46 μM). SET2 blocks the TRP channel and suppresses prostate cancer cells migration. SET2 reduces the lysophosphatidic acid (LPA, a TRPV2 activator)-induced cytoplasmic calcium increases .

HY-18075

LPA2 antagonist 1 4 Publications Verification	LPL Receptor	Cancer
LPA2 antagonist 1 is a *LPA2* antagonist with an IC₅₀ of 17 nM.

HY-114379

AS2717638 2 Publications Verification	LPL Receptor	Neurological Disease Inflammation/Immunology
AS2717638 is a highly selective, brain-penetrant and orally active lysophosphatidic acid receptor 5 (LPA5) antagonist with an IC₅₀ value of 38 nM. AS2717638 is highly selective and shows no significant antagonistic activity against other LPA receptors (LPA1, LPA2, and LPA3). AS2717638 can be used in the research of pain and neuroinflammation-related diseases .

HY-107616

H2L5186303 3 Publications Verification	LPL Receptor Apoptosis	Inflammation/Immunology
H2L5186303 is a potent and selective *LPA₂* receptor antagonist with an IC₅₀ of 9 nM. H2L5186303 promotes Apoptosis. H2L5186303 inhibits cell proliferation and motility. H2L5186303 has anti-inflammatory effects .

HY-145561

Cudetaxestat BLD-0409; PAT-409	Phosphodiesterase (PDE) LPL Receptor	Inflammation/Immunology Cancer
Cudetaxestat (BLD-0409; PAT-409) is an orally active and noncompetitive autotaxin (ATX) inhibitor. Cudetaxestat inhibits the activity of ATX, reduces the production of *LPA, and thereby blocks the signal transduction of the ATX-LPA* axis. Cudetaxestat can still maintain nanomolar-level biochemical efficacy even when the concentration of the LPC substrate increases. Cudetaxestat can be used for the study of various diseases related to LPA including fibrosis, tumor metastasis, inflammation and autoimmune diseases, etc .

HY-100882

ONO-7300243	LPL Receptor	Cardiovascular Disease
ONO-7300243 is a novel, potent lysophosphatidic acid receptor 1 (LPA1) antagonist with IC₅₀ of 0.16 μM.

HY-153492A

Olpasiran sodium AMG 890 sodium; ARC-LPA sodium	Small Interfering RNA (siRNA)	Inflammation/Immunology
Olpasiran (AMG 890, ARC-LPA) sodium is an N-acetyl galactosamine (GalNAc)-conjugated, hepatocyte-targeted siRNA. Olpasiran sodium directly inhibits LPA messenger RNA translation in hepatocytes and potently reduce Lp(a) concentration. Olpasiran sodium can be used for the research of cardiovascular disease, such as atherosclerosis .

HY-107615

*TC LPA5 4*	LPL Receptor	Cancer
TC LPA5 4 is a LPA₅ (GPR92)-specific non-lipid antagonist. TC LPA5 4 inhibits LPA-induced aggregation of isolated human platelet (LPA₅-RH7777 cell line) with an IC₅₀ of 800 nM. TC LPA5 4 displays selectivity for LPA₅ over 80 other screened agent targets . TC LPA5 4 inhibits cell proliferation and migration of thyroid cancer cells .

HY-157693

C18:1 Cyclic LPA	Endogenous Metabolite	Cancer
C18:1 Cyclic LPA is a naturally occurring analog of the growth factor-like phospholipid mediator, lysophosphatidic acid (LPA), characterized by the formation of a 5-membered ring between its sn-2 hydroxy group and the sn-3 phosphate. This unique structure allows C18:1 Cyclic LPA to influence a variety of cellular functions, such as inhibiting cell cycle progression, promoting the formation of stress fibers, curtailing tumor cell invasiveness and metastasis, and modulating the differentiation and survival of neuronal cells. Notably, many of these cellular effects elicited by C18:1 Cyclic LPA appear to counter those induced by LPA, despite the activation of seemingly similar receptor populations.

HY-18076

LPA1 receptor antagonist 1	LPL Receptor	Infection Inflammation/Immunology
LPA1 receptor antagonist 1 is a highly selective Lysophosphatidic Acid receptor-1 *(LPA1)* antagonist with an IC₅₀ of 25 nM.

HY-120797

CRT0273750 IOA-289	LPL Receptor	Cancer
CRT0273750 is an autotaxin (ATX) inhibitor and modulates LPA levels in plasm (IC₅₀ = 0.014 μM). CRT0273750 can be used in ATX/LPA-dependent models of cancer .

HY-124772

BI-2545 1 Publications Verification	Phosphodiesterase (PDE)	Inflammation/Immunology
BI-2545, a chemical probe, is a potent autotaxin (ATX) inhibitor that significantly reduces LPA, with IC₅₀s of 2.2 nM and 3.4 nM for human ATX and rat ATX, respectively .

HY-100676

GRI977143	LPL Receptor Caspase	Inflammation/Immunology Cancer
GRI977143 is a specific LPA₂ receptor agonist, with an EC₅₀ of 3.3 μM .

HY-150204

ONO-0740556	LPL Receptor	Others
ONO-0740556 is a potent Gi-coupled human lysophosphatidic acid receptor 1 (LPA1) agonist with an EC₅₀ value of 0.26 nM .

HY-120967

(2S)-OMPT triethylamine, in ethanol:chloroform (1:1), 98%	p38 MAPK Akt Interleukin Related	Cancer
(2S)-OMPT (triethylamine), in ethanol:chloroform (1:1), 98%, Lysophosphatidic acid analogue, is a *LPA3* G-protein-coupled receptor agonist. (2S)-OMPT (triethylamine), in ethanol:chloroform (1:1), 98% selectively activates LPA3 G-protein-coupled receptor to trigger downstream cellular signaling events. (2S)-OMPT (triethylamine), in ethanol:chloroform (1:1), 98% induces calcium, IL-6 release in cancer cells and activates MAPK and Akt signaling pathways. (2S)-OMPT (triethylamine), in ethanol:chloroform (1:1), 98% can be used for the research of ovarian cancer .

HY-146956S

*Oleoyl LPA-d5*	Isotope-Labeled Compounds	Others
Oleoyl LPA-d₅ is deuterium labeled Oleoyl LPA.

HY-113973

LPA2 antagonist 2	LPL Receptor	Cancer
LPA2 antagonist 2 (H2L 5226501) is a selective *LPA₂* antagonist with an IC₅₀ of 28.3 nM and a K_i of 21.1 nM. LPA2 antagonist 2 is >480-fold more selective than LPA₃ (IC₅₀ of 13.85 μM) .

HY-15706

H2L 5765834 1 Publications Verification	LPL Receptor	Cardiovascular Disease
H2L 5765834 is an antagonist of lysophosphatidic acid receptors LPA₁, *LPA₃, and LPA₅, with IC₅₀*s of 94, 752, and 463 nM respectively .

HY-128127

NAEPA	LPL Receptor	Others
NAEPA, a phosphate-mimetic derivative, is a lysophosphatidic acid *(LPA) receptor* agonist .

HY-137862A

(Rac)-1-Oleoyl lysophosphatidic acid (Rac)-1-Oleoyl-sn-glycero-3-phosphate; (Rac)-1-Oleoyl-LPA	LPL Receptor Drug Isomer	Neurological Disease
(Rac)-1-Oleoyl lysophosphatidic acid is an isomer of 1-Oleoyl lysophosphatidic acid sodium (HY-107614). 1-Oleoyl lysophosphatidic acid sodium is a bioactive lipid that can activate the *LPA* receptors .

HY-114380

Radioprotectin-1	LPL Receptor	Others
Radioprotectin-1 is a potent and specific nonlipid agonist of lysophosphatidic acid receptor 2 (LPA₂), with an EC₅₀ value of 25 nM for murine LPA₂ subtype .

HY-117959

TAK-615	LPL Receptor	Inflammation/Immunology
TAK-615 is a negative allosteric modulator (NAM) of the *LPA1* receptor for the research of pulmonary fibrosis. TAK-615 binds the LPA1 receptor with high affinity (K_d high affinity of 1.7 nM and K_d low affinity of 14.5 nM) .

HY-158424

LSN3353871	LDLR	Cardiovascular Disease
LSN3353871 is a potent inhibitor of lipoprotein(a) (Lp(a)) that can binds to Kringle IV (KIV) 8, KIV7-8 and KIV5-8, with K_d of 756 nM, 605 nM and 423 nM, respectively. LSN3353871 disrupts the formation of Lp(a) with the IC50 of 1.69 μM. LSN3353871 has oral bioactivity .

HY-117444

ONO-9780307	LPL Receptor	Cancer
ONO-9780307 is a specific synthetic *LPA1* (lysophosphatidic acid receptor 1) antagonist with an IC₅₀ value of 2.7 nM .

HY-120967A

(2S)-OMPT	p38 MAPK Akt Interleukin Related	Cancer
(2S)-OMPT, Lysophosphatidic acid analogue, is a *LPA3* G-protein-coupled receptor agonist. (2S)-OMPT selectively activates LPA3 G-protein-coupled receptor to trigger downstream cellular signaling events. (2S)-OMPT induces calcium, IL-6 release in cancer cells and activates MAPK and Akt signaling pathways. (2S)-OMPT can be used for the research of ovarian cancer .

HY-138453

ACT-1016-0707 LPA1 receptor antagonist 2	LPL Receptor	Inflammation/Immunology
ACT-1016-0707 (Compound 49) is an orally active and selective *LPA1* receptor antagonist. ACT-1016-0707 can be used for the research of fibrotic diseases .

HY-120478

ASP6432	LPL Receptor	Infection
ASP6432 is a potent and selective type 1 lysophosphatidic acid receptor (LPA1) antagonist with IC₅₀s of 11 nM and 30 nM for human LPA1 and rat LPA1, respectively .

HY-18641

Ki16198	LPL Receptor	Cancer
Ki16198 is a potent and orally active LPA receptor antagonist, the methyl ester of Ki16425 (HY-13285). Ki16198 inhibits LPA₁ and LPA₃-induced inositol phosphate production with?K_i?values of 0.34 μM and 0.93 μM, respectively. Ki16198 is effective for pancreatic cancer tumorigenesis and metastasis in vivo .

HY-171464

Lp(a)-IN-5	Apolipoprotein	Cardiovascular Disease
Lp(a)-IN-5 (Compound A) is an orally active lipoprotein (a) (Lp(a)) inhibitor. Lp(a)-IN-5 inhibits the assembly of Apo(a) and ApoB proteins with an IC₅₀ value of 0.41 nM. Lp(a)-IN-5 is promising for research of diseases related to elevated plasma Lp(a) levels, such as cardiovascular diseases .

HY-116100A

HA155	Phosphodiesterase (PDE)	Inflammation/Immunology
HA-155 is a potent and selective autotaxin (ATX) inhibitor with an IC₅₀ of 5.7 nM .

HY-W127502

1-Hexadecyl lysophosphatidic acid 1-Hexadecyl LPA; 1-Palmityl LPA; LPA O-16:0	Biochemical Assay Reagents	Others
1-Hexadecyl lysophosphatidic acid is an ether analog of lysophosphatidic acid (LPA) containing a hexadecyl group in the sn-1 position. LPA binds to five different G protein-coupled receptors and mediates a variety of biological responses, including cell proliferation, smooth muscle contraction, platelet aggregation, neurite contraction, and cell motility.

HY-151391

LPA5 antagonist 1	Biochemical Assay Reagents	Neurological Disease
LPA5 antagonist 1 (Compound 66) is a potent and selective lysophosphatidic acid receptor 5 (LPA5) antagonist (IC₅₀=32 nM). LPA5 antagonist 1 shows high blood-brain-barrier permeability and anti-nociceptive activity. LPA5 antagonist 1 can be used in inflammatory and neuropathic pain research . LPA5 antagonist 1 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-103267

S32826 disodium	Phosphodiesterase (PDE)	Inflammation/Immunology
S32826 disodium is a potent autotaxin inhibitor, with an IC₅₀ of 8.8 nM. S32826 disodium shows similar inhibitory effects at various autotaxin isoforms (α, β and γ). S32826 disodium inhibits LPA release from adipocytes .

HY-167862A

UCM-05194 ammonium	LPL Receptor	Neurological Disease
UCM-05194 (ammonium) is a lysophosphatidic acid receptor 1 (LPA1) agonist. UCM-05194 (ammonium) induces calcium mobilization in LPA1-expressing RH7777 cells (EC₅₀ = 0.24 µM). UCM-05194 (ammonium) induces neurite retraction and migration in LPA1-overexpressing B103 rat neuroblastoma cells. UCM-05194 (ammonium) attenuates acetic acid-induced writhing and hind paw mechanical hypersensitivity in mice .

HY-171464A

Lp(a)-IN-5 hydrochloride	Apolipoprotein	Cardiovascular Disease
Lp(a)-IN-5 (Compound A) hydrochloride is an orally active lipoprotein (a) (Lp(a)) inhibitor. Lp(a)-IN-5 hydrochloride inhibits the assembly of Apo(a) and ApoB proteins with an IC₅₀ value of 0.41 nM. Lp(a)-IN-5 hydrochloride is promising for research of diseases related to elevated plasma Lp(a) levels, such as cardiovascular diseases .

HY-146955S

*Linoleoyl LPA-d5*	Isotope-Labeled Compounds	Others
Linoleoyl LPA-d₅ is deuterium labeled Linoleoyl LPA.

HY-W040176

N-PTyrosine PA ammonium N-Palmitoyl-tyrosine phosphoric acid ammonium	LPL Receptor	Cardiovascular Disease Neurological Disease Inflammation/Immunology
N-PTyrosine PA (N-Palmitoyl-tyrosine phosphoric acid) ammonium is a *lysophosphatidic acid (LPA) receptor* modulator, which exhibits weak inhibitory activity against *LPA1* and partial agonist properties towards *LPA5. N-PTyrosine PA ammonium inhibits the activation of LPA* receptors and downstream responses by competing with agonists for binding sites. N-PTyrosine PA ammonium can induce morphological changes and aggregation, and also inhibit LPA-induced morphological changes through receptor desensitization caused by pre-incubation. N-PTyrosine PA ammonium can be used in the research of related diseases such as atherosclerosis and acute ischemic syndromes (e.g., unstable angina, myocardial infarction, stroke) .

HY-139133

L-NASPA	LPL Receptor	Inflammation/Immunology
L-NASPA is a ophosphatidic acid (LPA) inhibitor useful in the study of platelet activation .

HY-107614G

1-Oleoyl lysophosphatidic acid sodium 1-Oleoyl-sn-glycero-3-phosphate sodium; 1-Oleoyl-LPA sodium	LPL Receptor ROCK TGF-beta/Smad TGF-β Receptor	Neurological Disease Cancer
1-Oleoyl lysophosphatidic acid sodium (GMP) is the GMP-grade form of 1-Oleoyl lysophosphatidic acid sodium (HY-107614). GMP-grade small molecules serve as auxiliary reagents in cell therapy. 1-Oleoyl lysophosphatidic acid sodium is a bioactive lipid signaling molecule. 1-Oleoyl lysophosphatidic acid sodium inhibits lysoPLD-catalyzed hydrolysis of lysophosphatidylcholine and FS-3. 1-Oleoyl lysophosphatidic acid sodium activates *LPA₁* and *LPA₂, thereby triggering calcium mobilization, NFATc1* translocation, Rho/ROCK activation, Smad2/3 phosphorylation and c-Fos expression. 1-Oleoyl lysophosphatidic acid sodium induces anxiety-like, depression-like and hypoactivity phenotypes, regulates osteoclast cytoskeleton and viability, reduces osteoclast bone resorptive activity, and drives mesenchymal stem cell differentiation into myofibroblast-like cells. 1-Oleoyl lysophosphatidic acid sodium stimulates the secretion of transforming growth factor-β1 and stromal cell-derived factor-1. 1-Oleoyl lysophosphatidic acid sodium is applicable to research related to anxiety, depression and ovarian cancer .

HY-N15794

AzoLPA ammonium	LPL Receptor	Neurological Disease
AzoLPA ammonium is a photoswitchable lipid that activates the *Lysophosphatidic acid 1-5 (LPA1-5) receptors*’ signaling .

HY-167862

UCM-05194	Endogenous Metabolite	Neurological Disease
UCM-05194 is a selective LPA1 receptor agonist with activity to improve neuropathic pain. UCM-05194 is a LPA1 agonist that exhibits potent and selective properties in its pharmacologically similar properties. UCM-05194 triggers LPA1-mediated cellular effects and leads to internalization of the receptor, resulting in functional inactivation in primary sensory neurons. UCM-05194 effectively reduces pain perception in in vivo models. UCM-05194 can be used to conduct research on progressive systemic diseases .

HY-148291

*BrP-LPA* sodium**	LPL Receptor Phosphodiesterase (PDE)	Cancer
BrP-LPA sodium is a pan-opposite agent for lysophosphatidic acid (LPA). It has antagonistic activity against *LPA₁* (IC₅₀ = 4520 nM), *LPA₂* (IC₅₀ = 468 nM), *LPA₃, and LPA₄. BrP-LPA* sodium also has partial agonistic activity for *LPA₅, with its EC₅₀* being 1282 nM. BrP-LPA sodium has ATX inhibitory activity. BrP-LPA sodium effectively inhibits the migration and invasion of breast cancer cells. BrP-LPA sodium achieves tumor regression and anti-angiogenesis in mice breast cancer xenograft model. BrP-LPA sodium can be used for the study of breast cancer .

HY-126233

PAT-347	Phosphodiesterase (PDE)	Metabolic Disease
PAT-347 is an Autotaxin (ATX) inhibitor. ATX is a secretory enzyme that hydrolyzes lysophosphatidylcholine (LPC) and regulates lysophosphatidic acid (LPA) production in the blood .

Cat. No.	Product Name	Type

HY-107614G

1-Oleoyl lysophosphatidic acid sodium

1-Oleoyl-sn-glycero-3-phosphate sodium; 1-Oleoyl-LPA sodium

Fluorescent Dye

1-Oleoyl lysophosphatidic acid sodium (GMP) is the GMP-grade form of 1-Oleoyl lysophosphatidic acid sodium (HY-107614). GMP-grade small molecules serve as auxiliary reagents in cell therapy. 1-Oleoyl lysophosphatidic acid sodium is a bioactive lipid signaling molecule. 1-Oleoyl lysophosphatidic acid sodium inhibits lysoPLD-catalyzed hydrolysis of lysophosphatidylcholine and FS-3. 1-Oleoyl lysophosphatidic acid sodium activates LPA₁ and LPA₂, thereby triggering calcium mobilization, NFATc1 translocation, Rho/ROCK activation, Smad2/3 phosphorylation and c-Fos expression. 1-Oleoyl lysophosphatidic acid sodium induces anxiety-like, depression-like and hypoactivity phenotypes, regulates osteoclast cytoskeleton and viability, reduces osteoclast bone resorptive activity, and drives mesenchymal stem cell differentiation into myofibroblast-like cells. 1-Oleoyl lysophosphatidic acid sodium stimulates the secretion of transforming growth factor-β1 and stromal cell-derived factor-1. 1-Oleoyl lysophosphatidic acid sodium is applicable to research related to anxiety, depression and ovarian cancer .

Cat. No.	Product Name	Type

HY-120967

(2S)-OMPT triethylamine, in ethanol:chloroform (1:1), 98%

Biochemical Assay Reagents

(2S)-OMPT (triethylamine), in ethanol:chloroform (1:1), 98%, Lysophosphatidic acid analogue, is a LPA3 G-protein-coupled receptor agonist. (2S)-OMPT (triethylamine), in ethanol:chloroform (1:1), 98% selectively activates LPA3 G-protein-coupled receptor to trigger downstream cellular signaling events. (2S)-OMPT (triethylamine), in ethanol:chloroform (1:1), 98% induces calcium, IL-6 release in cancer cells and activates MAPK and Akt signaling pathways. (2S)-OMPT (triethylamine), in ethanol:chloroform (1:1), 98% can be used for the research of ovarian cancer .

HY-W127502

1-Hexadecyl lysophosphatidic acid 1-Hexadecyl LPA; 1-Palmityl LPA; LPA O-16:0	Biochemical Assay Reagents
1-Hexadecyl lysophosphatidic acid is an ether analog of lysophosphatidic acid (LPA) containing a hexadecyl group in the sn-1 position. LPA binds to five different G protein-coupled receptors and mediates a variety of biological responses, including cell proliferation, smooth muscle contraction, platelet aggregation, neurite contraction, and cell motility.

HY-139133

L-NASPA	Biochemical Assay Reagents
L-NASPA is a ophosphatidic acid (LPA) inhibitor useful in the study of platelet activation .

HY-107614G

1-Oleoyl lysophosphatidic acid sodium

1-Oleoyl-sn-glycero-3-phosphate sodium; 1-Oleoyl-LPA sodium

Biochemical Assay Reagents

HY-157617

*16:0 Cyclic LPA* ammonium** 1-Palmitoyl-sn-glycero-2,3-cyclic-phosphate ammonium	Biochemical Assay Reagents
16:0 Cyclic LPA (1-Palmitoyl-sn-glycero-2,3-cyclic-phosphate) ammonium is a palmitoyl cyclic phosphatidic acid .

HY-157669

1-Oleoyl-sn-glycero-2,3-cyclic-phosphate ammonium 18:1 Cyclic LPA	Biochemical Assay Reagents
1-Oleoyl-sn-glycero-2,3-cyclic-phosphate ammonium (18:1 Cyclic LPA) is a cyclic phosphatidic acid that can be used for the preparation of liposomes .

Cat. No.	Product Name	Target	Research Area	Image

HY-P991310

Lpathomab LT3015; LT-3000	LPL Receptor	Neurological Disease Cancer
Lpathomab (LT3015; LT-3000) is a human IgG1 monoclonal antibody (mAb) targeting *LPA. Lpathomab reduces the release of IL-8 and IL-6 cytokines in SKOV3 cells and blocks LPA*-triggered tumor cell migration. Lpathomab reduces neovascularization in Matrigel plug and CNV models. Lpathomab inhibits brain injury in the CCI mouse model. Lpathomab can be used in the study of brain injury, ovarian cancer, diabetic neuropathy, and spinal cord injury. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .

HY-P992262

*Anti-LPA/Lysophosphatidic acid Antibody (504B3)*

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N15794

AzoLPA ammonium	Lipid	LPL Receptor
AzoLPA ammonium is a photoswitchable lipid that activates the *Lysophosphatidic acid 1-5 (LPA1-5) receptors*’ signaling .

HY-N16000

*12:0 Biotinyl LPA* ammonium**	Lipid	Biochemical Assay Reagents
12:0 Biotinyl LPA ammonium is a biotinylated lipid.

HY-N15931

*18:1 1,3-Cyclic LPA* ammonium**	Lipid	Biochemical Assay Reagents
18:1 1,3-Cyclic LPA ammonium is a cyclic phosphatidic acid.

Cat. No.	Product Name	Chemical Structure

HY-146956S

*Oleoyl LPA-d5*
Oleoyl LPA-d₅ is deuterium labeled Oleoyl LPA.

HY-146955S

*Linoleoyl LPA-d5*
Linoleoyl LPA-d₅ is deuterium labeled Linoleoyl LPA.

HY-146945S

*Arachidonoyl LPA-d5*
Arachidonoyl LPA-d₅ is deuterium labeled Arachidonoyl LPA.

HY-174267S

ATX-IN-2
ATX-IN-2 (Compound 25) is an orally active and potent ATX inhibitor with an IC₅₀ value of 3.27 nM. ATX-IN-2 reduces lysophosphatidic acid (LPA) secretion. ATX-IN-2 is promising for research of ATX-mediated diseases, such as inflammation, pulmonary fibrosis .

HY-126967AS

1-Palmitoyl-sn-glycerol 3-phosphate-d9
1-Palmitoyl-sn-glycerol 3-phosphate-d9 is the deuterium labeled 1-Palmitoyl-sn-glycerol 3-phosphate (1-Palmitoyl LPA). 1-Palmitoyl LPA is an analog of LPA that contains palmitic acid at the sn-1 position.

Host:	Mouse (3) Rabbit (2)
Reactivity:	Human (5)
Application:	IHC-P (4) ICC/IF (4) IP (1) WB (3) FC (1) ELISA (3)
Isotype:	IgG (2) IgG1 (2)
Conjugation:	Non-conjugated (5)
Clonality:	Monoclonal (4) Recombinant (2)
Modification:	Unmodified (4)

Cat. No.	Compare	Product Name	Application	Reactivity	Image

HY-P82987

	ApoA Antibody (YA2732) LPA; Apolipoprotein(a; Apo(a); Lp(a)	WB	Human
	ApoA Antibody (YA2732) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to ApoA.

HY-P85037

	ApoA Antibody (YA4729) LPA; Apolipoprotein; a; Apo; a; Lp; a;	WB, IHC-P, ICC/IF, ELISA	Human
	ApoA Antibody (YA4729) is a Mouse-derived and non-conjugated monoclonal antibody, targeting to ApoA.

HY-P84010

	LPA Antibody (YA3707) LP; AK38; APOA; LPA	IHC-P, ICC/IF, ELISA	Human
	LPA Antibody (YA3707) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to LPA.

HY-P84010A

	LPA Antibody (YA3707)(PBS only) LP; AK38; APOA; LPA	IHC-P, ICC/IF, ELISA	Human
	LPA Antibody (YA3707) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to LPA.

HY-P83630

	EDG2 Antibody (YA3375) Lysophosphatidic acid receptor 1; LPA receptor 1; LPA-1; Lysophosphatidic acid receptor Edg-2; LPAR1; EDG2; LPA1	WB, IHC-P, ICC/IF, FC, IP	Human
	EDG2 Antibody (YA3375) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to EDG2.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name		Classification

HY-151391

LPA5 antagonist 1		Alkynes
LPA5 antagonist 1 (Compound 66) is a potent and selective lysophosphatidic acid receptor 5 (LPA5) antagonist (IC₅₀=32 nM). LPA5 antagonist 1 shows high blood-brain-barrier permeability and anti-nociceptive activity. LPA5 antagonist 1 can be used in inflammatory and neuropathic pain research . LPA5 antagonist 1 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

Cat. No.	Product Name		Classification

HY-153492A

Olpasiran sodium AMG 890 sodium; ARC-LPA sodium		siRNAs siRNA drugs
Olpasiran (AMG 890, ARC-LPA) sodium is an N-acetyl galactosamine (GalNAc)-conjugated, hepatocyte-targeted siRNA. Olpasiran sodium directly inhibits LPA messenger RNA translation in hepatocytes and potently reduce Lp(a) concentration. Olpasiran sodium can be used for the research of cardiovascular disease, such as atherosclerosis .

HY-157693

C18:1 Cyclic LPA		Phospholipids
C18:1 Cyclic LPA is a naturally occurring analog of the growth factor-like phospholipid mediator, lysophosphatidic acid (LPA), characterized by the formation of a 5-membered ring between its sn-2 hydroxy group and the sn-3 phosphate. This unique structure allows C18:1 Cyclic LPA to influence a variety of cellular functions, such as inhibiting cell cycle progression, promoting the formation of stress fibers, curtailing tumor cell invasiveness and metastasis, and modulating the differentiation and survival of neuronal cells. Notably, many of these cellular effects elicited by C18:1 Cyclic LPA appear to counter those induced by LPA, despite the activation of seemingly similar receptor populations.

HY-120967A

(2S)-OMPT		Phospholipids
(2S)-OMPT, Lysophosphatidic acid analogue, is a *LPA3* G-protein-coupled receptor agonist. (2S)-OMPT selectively activates LPA3 G-protein-coupled receptor to trigger downstream cellular signaling events. (2S)-OMPT induces calcium, IL-6 release in cancer cells and activates MAPK and Akt signaling pathways. (2S)-OMPT can be used for the research of ovarian cancer .

HY-145486

1-Arachidonoyl-sn-glycerol 3-phosphate ammonium 20:4 Lyso PA		Phospholipids
1-Arachidonoyl-sn-glycerol 3-phosphate ammonium (20:4 Lyso PA) is a phospholipid and an LPA derived from arachidonic acid. The concentration of 1-Arachidonoyl-sn-glycerol 3-phosphate ammonium in plasma is significantly correlated with the age of onset of cocaine use and the duration of abstinence. 1-Arachidonoyl-sn-glycerol 3-phosphate ammonium can be used in the research of biomarkers for cocaine use disorder (CUD) .

HY-157725

C18:1 LPA		Phospholipids
C18:1 LPA, a bioactive lipid derived from membrane phospholipids, plays a crucial role in various cellular processes and is found in blood plasma, where it is linked to neurological disorders, inflammation, and cancer.

HY-W040175

L-NASPA ammonium		Phospholipids
L-NASPA ammonium is a ophosphatidic acid (LPA) inhibitor useful in the study of platelet activation .

HY-W783254

C18 LPA PA(18:0e/0:0)		Phospholipids
C18 LPA (PA(18:0e/0:0)) is a water-soluble phospholipid that functions as a signaling molecule, influencing various cellular responses through G protein-coupled receptors (GPCRs). It is known to promote smooth muscle contraction, cytoskeletal rearrangement, and chemotaxis, while also playing a role in neurotransmitter release, cell proliferation, platelet aggregation, and Ca2+ mobilization. Elevated levels of C18 LPA in human plasma are associated with ovarian cancer and atherosclerosis, suggesting its potential as a biomarker for ovarian cancer.

HY-RS07745

LPA Human Pre-designed siRNA Set A		siRNAs Human Pre-designed siRNA Sets
LPA Human Pre-designed siRNA Set A contains three designed siRNAs for LPA gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-157617

*16:0 Cyclic LPA* ammonium** 1-Palmitoyl-sn-glycero-2,3-cyclic-phosphate ammonium		Phospholipids
16:0 Cyclic LPA (1-Palmitoyl-sn-glycero-2,3-cyclic-phosphate) ammonium is a palmitoyl cyclic phosphatidic acid .

HY-W725317

*C16 LPA* ammonium** PA(16:0e/0:0) ammonium		Phospholipids
C16 LPA (PA(16:0e/0:0)) ammonium is a lipid that can be used to prepare lipid nanoparticles (LNPs) for drug delivery.

HY-157669

1-Oleoyl-sn-glycero-2,3-cyclic-phosphate ammonium 18:1 Cyclic LPA		Phospholipids
1-Oleoyl-sn-glycero-2,3-cyclic-phosphate ammonium (18:1 Cyclic LPA) is a cyclic phosphatidic acid that can be used for the preparation of liposomes .

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-107614G

1-Oleoyl lysophosphatidic acid sodium 1-Oleoyl-sn-glycero-3-phosphate sodium; 1-Oleoyl-LPA sodium	LPL Receptor ROCK TGF-beta/Smad TGF-β Receptor	Neurological Disease Cancer
1-Oleoyl lysophosphatidic acid sodium (GMP) is the GMP-grade form of 1-Oleoyl lysophosphatidic acid sodium (HY-107614). GMP-grade small molecules serve as auxiliary reagents in cell therapy. 1-Oleoyl lysophosphatidic acid sodium is a bioactive lipid signaling molecule. 1-Oleoyl lysophosphatidic acid sodium inhibits lysoPLD-catalyzed hydrolysis of lysophosphatidylcholine and FS-3. 1-Oleoyl lysophosphatidic acid sodium activates *LPA₁* and *LPA₂, thereby triggering calcium mobilization, NFATc1* translocation, Rho/ROCK activation, Smad2/3 phosphorylation and c-Fos expression. 1-Oleoyl lysophosphatidic acid sodium induces anxiety-like, depression-like and hypoactivity phenotypes, regulates osteoclast cytoskeleton and viability, reduces osteoclast bone resorptive activity, and drives mesenchymal stem cell differentiation into myofibroblast-like cells. 1-Oleoyl lysophosphatidic acid sodium stimulates the secretion of transforming growth factor-β1 and stromal cell-derived factor-1. 1-Oleoyl lysophosphatidic acid sodium is applicable to research related to anxiety, depression and ovarian cancer .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

LPA

Inhibitors & Agonists

Fluorescent Dye

Biochemical Assay Reagents

Inhibitory Antibodies

NaturalProducts

Isotope-Labeled Compounds

Antibodies

Click Chemistry

Oligonucleotides

GMP Molecules

Natural
Products